Clinical Trials Logo

Clinical Trial Summary

Prospective, randomized, open-label, controlled clinical trial to evaluate the efficacy and tolerability of Alpha Lipoic Acid administration on oxidative stress, inflammatory markers, clinical outcome and occurrence of No-Reflow in post myocardial infarction (MI) patients by assessment of aldehyde dehydrogenase-2 (ALDH2) as a marker of oxidative stress and paraoxonase-1 (PON-1) as a marker of oxidative stress and inflammation.


Clinical Trial Description

All (60) STEMI patients undergoing PCI presenting to the Cardiology department will be randomly assigned into one of 2 arms: 30 patients undergoing PCI who will receive standard of care for 1 week, the other 30 patients undergoing PCI will receive standard of care in addition to Alpha Lipoic Acid 600 mg daily for 1 week. IV Alpha Lipoic Acid 600 mg once daily will be administered prior to PCI then orally daily for 1 week after PCI. Baseline evaluation included demographics and history taking. After obtaining the informed consent, information including age, weight, height, smoking state, and other diseases e.g. hypertension, diabetes, hyperlipidemias, etc. will be documented for each patient. Medication history in detail, as well as the background cardiovascular treatment, will be considered. All patients will be followed up regularly during the hospital stay and after discharge, will be assessed for the occurrence of adverse cardiac events and occurrence of adverse effects from medications ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05360602
Study type Interventional
Source Ain Shams University
Contact Omar Ragab Elsayed, BSc
Phone 00201011177942
Email omar.ragab@pharma.asu.edu.eg
Status Not yet recruiting
Phase N/A
Start date July 1, 2022
Completion date August 2023

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03264859 - NGAL and Its Association With the No-reflow Phenomenon in ST-elevation Myocardial Infarction N/A
Completed NCT04785209 - Mean Platelet Volume and STEMI Clinical Risk Scores in Prediction of Impaired Myocardial Perfusion In Acute STEMI Patients Undergoing Primary Percutaneous Coronary Intervention.
Not yet recruiting NCT06342141 - Empagliflozin for No-reflow Phenomenon in PCI for STEMI Phase 2
Not yet recruiting NCT04835974 - the No-reflow in Diabetic Patients Treated With Primary Percutaneous Coronary Intervention (PCI) N/A
Completed NCT02054000 - Intracoronary Tirofiban on No-Reflow Phenomena Phase 4
Not yet recruiting NCT05393557 - Upfront Premedication For Reduction of Microvascular Obstruction and No-reflow in Treating ST-segment Elevation Myocardial Infarction N/A
Completed NCT04699110 - Adrenaline for the Treatment of No-Reflow in Normotensive Patients Phase 4
Completed NCT04573751 - The EPIVER Randomized Controlled Trial N/A
Not yet recruiting NCT02233790 - Ticagrelor and Clopidogrel on Reperfusion in Patients With AMI Phase 4
Recruiting NCT05427786 - A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT reductioN Of decREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease Phase 4
Completed NCT05355532 - Genetic Determinants of the Coronary Microvascular Obstruction in PCI